WO1996005837A1 - Verwendung von n-substituierten phenothiazinen - Google Patents
Verwendung von n-substituierten phenothiazinen Download PDFInfo
- Publication number
- WO1996005837A1 WO1996005837A1 PCT/EP1995/003212 EP9503212W WO9605837A1 WO 1996005837 A1 WO1996005837 A1 WO 1996005837A1 EP 9503212 W EP9503212 W EP 9503212W WO 9605837 A1 WO9605837 A1 WO 9605837A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenothiazine
- carbon atoms
- straight
- chain
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/26—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom without other substituents attached to the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/30—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with acyl radicals attached to the ring nitrogen atom
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU33453/95A AU3345395A (en) | 1994-08-25 | 1995-08-14 | Use of n-substituted phenothiazines |
JP8507759A JPH10504820A (ja) | 1994-08-25 | 1995-08-14 | N−置換されたフェノチアジン類の使用 |
EP95929864A EP0777481A1 (de) | 1994-08-25 | 1995-08-14 | Verwendung von n-substituierten phenothiazinen |
US08/793,619 US5861394A (en) | 1994-08-25 | 1995-08-14 | Use of N-substituted phenothiazines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4430091.3 | 1994-08-25 | ||
DE4430091A DE4430091A1 (de) | 1994-08-25 | 1994-08-25 | Verwendung von N-substituierten Phenothiazinen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996005837A1 true WO1996005837A1 (de) | 1996-02-29 |
Family
ID=6526496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003212 WO1996005837A1 (de) | 1994-08-25 | 1995-08-14 | Verwendung von n-substituierten phenothiazinen |
Country Status (11)
Country | Link |
---|---|
US (1) | US5861394A (de) |
EP (1) | EP0777481A1 (de) |
JP (1) | JPH10504820A (de) |
AU (1) | AU3345395A (de) |
CA (1) | CA2198256A1 (de) |
DE (1) | DE4430091A1 (de) |
IL (1) | IL115027A (de) |
MY (1) | MY132077A (de) |
TW (1) | TW408117B (de) |
WO (1) | WO1996005837A1 (de) |
ZA (1) | ZA957113B (de) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004554A1 (fr) * | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonistes de recepteurs de chemokines |
WO2001092240A1 (en) * | 2000-05-29 | 2001-12-06 | Dalhousie University | Novel n-substituted phenothiazines and their use as modulators of serine hydrolase enzymes |
WO2002075318A3 (en) * | 2001-03-20 | 2004-03-11 | Univ Aberdeen | Neurofibrillary labels |
WO2008009935A1 (en) * | 2006-07-19 | 2008-01-24 | Ucl Business Plc | Pharmaceutical compositions and their use |
US7335505B2 (en) | 2001-01-15 | 2008-02-26 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
US7534786B2 (en) | 1995-03-27 | 2009-05-19 | Wista Laboratories Ltd. | Inhibition of tau-tau association |
US7737138B2 (en) | 2004-09-23 | 2010-06-15 | Wista Laboratories Ltd. | Methods of treatment of a tauopathy condition comprising the use of thioninium compounds |
US7834237B2 (en) | 2001-01-03 | 2010-11-16 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
US7888350B2 (en) | 2006-03-29 | 2011-02-15 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
US8263589B2 (en) | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
US10864216B2 (en) | 2011-02-11 | 2020-12-15 | Wista Laboratories, Ltd. | Phenothiazine diaminium salts and their use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6436972B1 (en) * | 2000-04-10 | 2002-08-20 | Dalhousie University | Pyridones and their use as modulators of serine hydrolase enzymes |
DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
US11084807B2 (en) | 2016-08-18 | 2021-08-10 | Vidac Pharama Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2303542A1 (fr) * | 1975-03-12 | 1976-10-08 | Fabre Sa Pierre | Amides de la pyrrolidino ethyl amine utilisables en therapeutique pulmonaire |
FR2326194A1 (fr) * | 1975-10-02 | 1977-04-29 | Fabre Sa Pierre | Phenothiazines carboxamides utilisables dans le traitement des syndromes extra-pyramidaux et de la maladie de parkinson |
JPS56166183A (en) * | 1980-05-26 | 1981-12-21 | Showa Denko Kk | Phenothazine derivative and carcinostatic agent |
US4833138A (en) * | 1987-10-23 | 1989-05-23 | Washington University | Phenothiazinealkaneamines for treatment of neurotoxic injury |
FR2689013A1 (fr) * | 1992-03-30 | 1993-10-01 | Rhone Poulenc Rorer Sa | Nouvelle application thérapeutique des dérivés de la phénothiazine. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7430M (de) * | 1968-05-06 | 1969-11-17 | ||
US4666907A (en) * | 1983-10-05 | 1987-05-19 | Merck Frosst Canada, Inc. | Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors |
-
1994
- 1994-08-25 DE DE4430091A patent/DE4430091A1/de not_active Withdrawn
-
1995
- 1995-07-14 TW TW084107282A patent/TW408117B/zh active
- 1995-08-14 EP EP95929864A patent/EP0777481A1/de not_active Ceased
- 1995-08-14 JP JP8507759A patent/JPH10504820A/ja active Pending
- 1995-08-14 CA CA002198256A patent/CA2198256A1/en not_active Abandoned
- 1995-08-14 AU AU33453/95A patent/AU3345395A/en not_active Abandoned
- 1995-08-14 US US08/793,619 patent/US5861394A/en not_active Expired - Fee Related
- 1995-08-14 WO PCT/EP1995/003212 patent/WO1996005837A1/de not_active Application Discontinuation
- 1995-08-18 MY MYPI95002437A patent/MY132077A/en unknown
- 1995-08-22 IL IL11502795A patent/IL115027A/xx not_active IP Right Cessation
- 1995-08-24 ZA ZA957113A patent/ZA957113B/xx unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2303542A1 (fr) * | 1975-03-12 | 1976-10-08 | Fabre Sa Pierre | Amides de la pyrrolidino ethyl amine utilisables en therapeutique pulmonaire |
FR2326194A1 (fr) * | 1975-10-02 | 1977-04-29 | Fabre Sa Pierre | Phenothiazines carboxamides utilisables dans le traitement des syndromes extra-pyramidaux et de la maladie de parkinson |
JPS56166183A (en) * | 1980-05-26 | 1981-12-21 | Showa Denko Kk | Phenothazine derivative and carcinostatic agent |
US4833138A (en) * | 1987-10-23 | 1989-05-23 | Washington University | Phenothiazinealkaneamines for treatment of neurotoxic injury |
FR2689013A1 (fr) * | 1992-03-30 | 1993-10-01 | Rhone Poulenc Rorer Sa | Nouvelle application thérapeutique des dérivés de la phénothiazine. |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, vol. 89, no. 23, 4 December 1978, Columbus, Ohio, US; abstract no. 190804, NAZAROVA L.S. ET AL: "Azacycloalkanes" * |
CHEMICAL ABSTRACTS, vol. 96, no. 17, 26 April 1982, Columbus, Ohio, US; abstract no. 142872, "Antitumor phenothiazine derivatives." * |
KHIM.-FARM.. ZH., vol. 12, no. 6, USSR, pages 84 - 89 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534786B2 (en) | 1995-03-27 | 2009-05-19 | Wista Laboratories Ltd. | Inhibition of tau-tau association |
US8278298B2 (en) | 1995-03-27 | 2012-10-02 | Wista Laboratories Ltd. | Inhibition of tau-tau-association |
US6140338A (en) * | 1996-07-29 | 2000-10-31 | Banyu Pharmaceutical, Co., Ltd. | Chemokine receptor antagonists |
WO1998004554A1 (fr) * | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Antagonistes de recepteurs de chemokines |
WO2001092240A1 (en) * | 2000-05-29 | 2001-12-06 | Dalhousie University | Novel n-substituted phenothiazines and their use as modulators of serine hydrolase enzymes |
US7834237B2 (en) | 2001-01-03 | 2010-11-16 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
US7893054B2 (en) | 2001-01-15 | 2011-02-22 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
US7335505B2 (en) | 2001-01-15 | 2008-02-26 | Wista Laboratories Ltd. | Materials and methods relating to protein aggregation in neurodegenerative disease |
WO2002075318A3 (en) * | 2001-03-20 | 2004-03-11 | Univ Aberdeen | Neurofibrillary labels |
US7335652B2 (en) | 2001-03-20 | 2008-02-26 | Wista Laboratories Ltd. | Neurofibrillary labels |
US7713962B2 (en) | 2001-03-20 | 2010-05-11 | Wista Laboratories Ltd. | Neurofibrillary labels |
US8097615B2 (en) | 2001-03-20 | 2012-01-17 | Wista Laboratories Ltd. | Neurofibrillary labels |
US7737138B2 (en) | 2004-09-23 | 2010-06-15 | Wista Laboratories Ltd. | Methods of treatment of a tauopathy condition comprising the use of thioninium compounds |
US7888350B2 (en) | 2006-03-29 | 2011-02-15 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
US8263589B2 (en) | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
US11344558B2 (en) | 2006-03-29 | 2022-05-31 | Wista Laboratories Ltd. | 3, 7-diamino-10H-phenothiazine salts and their use |
US8710051B2 (en) | 2006-03-29 | 2014-04-29 | Wis Ta Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
US9174954B2 (en) | 2006-03-29 | 2015-11-03 | Wista Laboratories Ltd. | 3,7-diamino-10H-phenothiazine salts and their use |
US11951110B2 (en) | 2006-03-29 | 2024-04-09 | Wista Laboratories Ltd. | 3, 7-diamino-10H-phenothiazine salts and their use |
WO2008009935A1 (en) * | 2006-07-19 | 2008-01-24 | Ucl Business Plc | Pharmaceutical compositions and their use |
US11180464B2 (en) | 2011-02-11 | 2021-11-23 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
US10864216B2 (en) | 2011-02-11 | 2020-12-15 | Wista Laboratories, Ltd. | Phenothiazine diaminium salts and their use |
Also Published As
Publication number | Publication date |
---|---|
MY132077A (en) | 2007-09-28 |
TW408117B (en) | 2000-10-11 |
IL115027A0 (en) | 1995-12-08 |
IL115027A (en) | 2000-01-31 |
DE4430091A1 (de) | 1996-02-29 |
EP0777481A1 (de) | 1997-06-11 |
US5861394A (en) | 1999-01-19 |
AU3345395A (en) | 1996-03-14 |
JPH10504820A (ja) | 1998-05-12 |
ZA957113B (en) | 1996-04-15 |
CA2198256A1 (en) | 1996-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0546388B1 (de) | Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems | |
DE4430638A1 (de) | Verwendung von substituierten 4-Phenyl-6-amino-nicotinsäurederivaten als Arzneimittel | |
EP0777481A1 (de) | Verwendung von n-substituierten phenothiazinen | |
WO1996006610A1 (de) | Verwendung von 5-substituierten pyridin- und hexahydrochinolin-3-carbonsäurederivaten zur behandlung von erkrankungen des zentralnervensystems | |
EP0546389B1 (de) | Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems | |
EP0539803B1 (de) | Triazaspirodecanon-Methyl-Chromane zur Bekämpfung von Erkrankungen des Zentralnervensystems | |
EP0622366B1 (de) | Kondensierte Chinolyl-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln zur Behandlung von Herz-Kreislauferkrangen | |
EP0705830A1 (de) | 2,3-Cyclisch kondensierte 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als selektive Kaliumkanalmodulatoren | |
EP0519291B1 (de) | Aminomethyl-substituierte 2,3-Dihydropyrano(2,3-b)pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
EP0770082A1 (de) | Dioxo-thiopyrano-pyridin-carbonsäure-derivate und ihre verwendung als arzneimittel | |
EP0758648B1 (de) | Substituierte 4H-Pyrane mit einer modulierende Wirkung auf Kaliumkanäle | |
EP0777663B1 (de) | Verwendung von substituierten 6-amino-4h-pyranen | |
EP0595166B1 (de) | 4-Heterocyclyl substituierte Dihydropyridine | |
EP0891322B1 (de) | Dimethyl-substituierte cyclohexandienderivate | |
DE4131346A1 (de) | Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
EP1047685A1 (de) | Substituierte beta,gamma-anellierte lactone | |
EP0698597A2 (de) | Cyclohexadienderivate | |
EP0758647A1 (de) | Acyl-substituierte Aminopyrane mit einer modulierende Wirkung auf Kaliumkanäle | |
DE4305456A1 (de) | 2-Alkyloxymethyl-indolsulfonamid-substituierte Dihydropyridine | |
DE4305455A1 (de) | 2-Ethylenoxyethyl-indolsulfonamid substituierte Dihydropyridine | |
DE4305457A1 (de) | 2-Alkyloxy-indolsulfonamid-substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
DE3431700A1 (de) | Neue 1,4-dihydro-pyridazin-derivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
EP0704434A1 (de) | 6-Amino-1,4-Dihydropyridinen und ihre Verwendung als selektive Kaliumkanalmodulatoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BY CA CN CZ EE FI HU JP KR LT LV MX NO NZ PL RU SI SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995929864 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08793619 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2198256 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1995929864 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1995929864 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995929864 Country of ref document: EP |